Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.38 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.38 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.38 |
| ▸ | TOP1 | P11387 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5525447 | 0.95 | PARP1 (0.39) | PARP1TNK2TNK1TOP1KDM4E | |
| SCHEMBL5527443 | 0.92 | TOP1 (0.46) | PARP1TNK2TNK1TOP1KDM4E | |
| SCHEMBL5524995 | 0.90 | TOP1 (0.38) | PARP1TOP1KDM4EALDH1A1POLB | |
| SCHEMBL5525220 | 0.89 | PIK3CG (0.37) | PARP1TOP1KDM4EALDH1A1POLB | |
| SCHEMBL14417363 | 0.89 | KDM4E (0.42) | TOP1KDM4EALDH1A1POLBHSP90AA1 | |
| SCHEMBL5525061 | 0.89 | TOP1 (0.36) | PARP1TOP1KDM4EALDH1A1HPGD | |
| SCHEMBL5529726 | 0.89 | CYP3A4 (0.42) | PARP1TNK2TNK1KDM4EALDH1A1 | |
| SCHEMBL5523363 | 0.87 | HPGD (0.41) | TOP1KDM4EALDH1A1POLBHSP90AA1 | |
| SCHEMBL5530782 | 0.86 | HPGD (0.46) | TOP1KDM4EALDH1A1POLBHSP90AA1 | |
| SCHEMBL5528922 | 0.86 | HPGD (0.42) | PARP1TNK2TNK1TOP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213339-A1 | Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-13 | — | — | US | claimed |
| US-20070213339-A1 | Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213339-A1 | Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213339-A1 | Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-13 | — | — | US | disclosed |
| EP-1732897-A1 | QUINOLONE CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE CONDITIONS | Bayer Pharmaceuticals Corporation (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005097752-A1 | QUINOLONE CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE CONDITIONS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213339-A1 | Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions | TP53, RB1, HRAS | PARP1 435/4885TNK2 832/4885TNK1 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.